DMII Drugs Made In America Acquisition II Corp. Ordinary Shares

QT66

NASDAQ·Financial Services·Financial - Conglomerates·USA

Latest market price

10.21

+0.01+0.10%

Overview Short InterestFilings

DMIIQT66Drugs Made In America Acquisition II Corp. Ordinary Shares·NASDAQ

Overview Short InterestFilings

10.21+0.10%

Loading chart...

Screen all →

XRPN-17.61%$11.70 RREV+0.05%$9.91 RILY-5.17%$3.85 ENHA-22.38%$7.32 FRHC+0.16%$187.30 TRU+3.18%$79.23 CRBG+0.66%$35.04 PNFP+2.62%$104.32

Snapshot

Index	—	P/E	—	EPS (ttm)	39.98	Insider Own	47.96%	Shs Outstand	63.70M	Perf Week	0.10%

Market Cap	650.38M	Forward P/E	—	EPS next Y	—	Insider Trans	—	Shs Float	49.59M	Perf Month	0.20%

Enterprise Value	650.38M	PEG	—	EPS next Q	—			Short Float	0.22%	Perf Quarter	0.99%

Income	4.00M	P/S	—	EPS this Y	—			Short Ratio	1.33	Perf Half Y	1.90%

Sales	0.00	P/B	1.31	EPS next Y	—	ROA	2.53%	Short Interest	111.24K	Perf YTD	3.13%

Book/sh	7.79	P/C	—	EPS next 5Y	—	ROE	2.66%	52W High	10.33 -1.16%	Perf Year	—

Cash/sh	0.00	P/FCF	—	EPS past 3/5Y	—	ROIC	-0.28%	52W Low	9.86 3.55%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	0.08% 0.10%	Perf 5Y	—

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	0.01	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	0.34	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	68.94	Recom	—

Dividend Gr. 3/5Y	—	Current Ratio	0.34	EPS Q/Q	—	SMA20	0.18%	Beta	-0.01	Target Price	—

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	—	SMA50	0.35%	Rel Volume	0.23	Prev Close	10.20

Employees	2	LT Debt/Eq	0.00	Earnings	—	SMA200	1.40%	Avg Volume	110.58K	Price	10.21

IPO Date	Dec 04, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	—	Net Debt/EBITDA	—	Volume	24,894	Change	0.10%

Company

Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024
Total Revenue	0	0
Cost of Goods Sold Incl. D&A	0	0
Gross Profit	0	0
Selling, General and Administrative Excl. Other	1	0
Research and Development	0	0
Other Operating Expense	0	0
Operating Income	-1	0
Interest Expense	0	0
Unusual Expense	—	—
Non-Operating Income (Expense)	5	0
Net Income Before Taxes	4	0
Income Taxes	0	0
Consolidated Net Income	4	0
Net Income From Continuing Operations	4	0
Net Income	4	0
EPS (Recurring)	0.07	-0.00
EPS (Basic, Before Extraordinaries)	0.07	-0.00
EPS (Diluted)	0.07	-0.00
EBITDA	-1	0
Other After Tax Adjustments	—	—
Stock Option Compensation Expense	—	—
Price To Earnings Ratio	152.31	—
Price To Sales Ratio	—	—
Gross Margin	—	—
Operating Margin	—	—
Net Margin	—	—
Shares Outstanding	64	64
Market Capitalization	634	—
Operating Lease Expense	—	—

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stockwell Lynn	CEO and Exe. Chair of Board	Sep 26 '25	Buy	0.00	1,400,000	0	15,075,000	Oct 01
Stockwell Lynn	CEO and Exe. Chair of Board	Sep 26 '25	Sale	1.50	7,966,667	11,950,001	6,708,333	Oct 01
Drugs Made In America Acquisition II LLC	10% Owner	Sep 26 '25	Buy	0.00	1,400,000	0	15,075,000	Oct 01
Drugs Made In America Acquisition II LLC	10% Owner	Sep 26 '25	Sale	1.50	7,966,667	11,950,001	6,708,333	Oct 01

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.